WO2001012804A2 - MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES - Google Patents

MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES Download PDF

Info

Publication number
WO2001012804A2
WO2001012804A2 PCT/US2000/022284 US0022284W WO0112804A2 WO 2001012804 A2 WO2001012804 A2 WO 2001012804A2 US 0022284 W US0022284 W US 0022284W WO 0112804 A2 WO0112804 A2 WO 0112804A2
Authority
WO
WIPO (PCT)
Prior art keywords
nucleoside
oligonucleotide
cpg dinucleotide
cpg
dinucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/022284
Other languages
English (en)
French (fr)
Other versions
WO2001012804A3 (en
Inventor
Sudhir Agrawal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aceragen Inc
Original Assignee
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybridon Inc filed Critical Hybridon Inc
Priority to CA002381993A priority Critical patent/CA2381993A1/en
Priority to DK00955527T priority patent/DK1200580T3/da
Priority to MXPA02001610A priority patent/MXPA02001610A/es
Priority to DE60017259T priority patent/DE60017259T2/de
Priority to JP2001517689A priority patent/JP5268214B2/ja
Priority to AT00955527T priority patent/ATE286534T1/de
Priority to AU67720/00A priority patent/AU783745B2/en
Priority to EP00955527A priority patent/EP1200580B1/en
Publication of WO2001012804A2 publication Critical patent/WO2001012804A2/en
Publication of WO2001012804A3 publication Critical patent/WO2001012804A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Definitions

  • the invention relates to the therapeutic use of oligonucleotides, both in the antisense approach, and as immunostimulatory agents.
  • Oligonucleotides have become indispensable tools in modern molecular biology, being used in a wide variety of techniques, ranging from diagnostic probing methods to PCR to antisense inhibition of gene expression. This widespread use of oligonucleotides has led to an increasing demand for rapid, inexpensive and efficient methods for synthesizing oligonucleotides.
  • oligonucleotides for antisense and diagnostic applications can now be routinely accomplished. See e.g., Methods in Molecular Biology, Vol. 20: Protocols for Oligonucleotides and Analogs pp. 165-189 (S. Agrawal, Ed., Humana Press, 1993); Oligonucleotides and
  • Crooke, Antisense Nucleic Acid Drug Dev. 8: vii-viii discloses the successful marketing approval of a phosphorothioate oligonucleotide for the treatment of human cytomegalovirus-induced retinitis.
  • the use of phosphorothioate oligonucleotides has become more complex than originally expected. Certain effects caused by phosphorothioate oligonucleotides could not be explained by the expected antisense mechanism. For example,
  • Mclntyre et al., Antisense Res. Dev. 3: 309-322 (1993) teaches that a "sense" phosphorothioate oligonucleotide causes specific immune stimulation. This and other side effects have complicated the picture for phosphorothioate oligonucleotides. Zhao et al, Biochemical Pharmacology 51:173-182 (1996) discloses immune stimulation mediated by two CpG-containing oligonucleotides, one complementary to the gag gene from HIV-1 (5'- CTCTCGCACCCATCTCTCTCCTTCT-3'), and the other complementary to the rev gene of HIV-1 (5'-TCGTCGCTGTCTCCGCTTCTTCTTGCC-3').
  • the invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides.
  • the methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.
  • the invention further provides oligonucleotides having optimal levels of immunostimulatory effect for either application and methods for using such oligonucleotides.
  • positional modification of CpG-containing oligonucleotides dramatically affects their immunostimulatory capabilities.
  • 2' alkylation or alkoxylation of oligonucleotides at particular positions 5' or 3' to the CpG dinucleotide either enhances or reduces their immunostimulatory effect.
  • the invention provides a method for reducing the immunostimulatory effect of a CpG-containing oligonucleotide.
  • the method according to this aspect of the invention comprises introducing a 2' substituted nucleoside into the oligonucleotide at a position adjacent to, and on the 5' side of the CpG dinucleotide, wherein at least one nucleoside is not a 2'-O-methylribonucleoside and the oligonucleotide is not complementary to the gag or rev gene of human immunodeficiency virus type 1.
  • the invention provides a CpG-containing oligonucleotide having a reduced immunostimulatory effect, wherein the oligonucleotide comprises a 2! substituted nucleoside at a position adjacent to, and on the 5' side of the CpG dinucleotide, wherein at least one nucleoside is not a 2'-0-methylribonucleoside and the oligonucleotide is not complementary to the gag or rev gene of human immunodeficiency virus type 1.
  • the invention provides a method for obtaining an antisense-specific reduction in the expression of a gene in a mammal, the method comprising administering to the mammal a CpG-containing oligonucleotide having a reduced immunostimulatory effect, wherein the oligonucleotide comprises a 2' substituted nucleoside at a position adjacent to, and on the 5' side of the CpG dinucleotide, wherein at least one nucleoside is not a 2'-0-methylribonucleoside and the oligonucleotide is not complementary to the gag or rev gene of human immunodeficiency virus type 1.
  • the invention provides a method for increasing the immunostimulatory effect of a CpG-containing oligonucleotide, wherein the oligonucleotide is not an antisense oligonucleotide complementary to Ha-ras or the gag or rev gene of human immunodeficiency virus type 1.
  • the method according to this aspect of the invention comprises introducing into the oligonucleotide a 2' substituted nucleoside at a position selected from the group consisting of 1st nucleoside 5' to the CpG dinucleotide , second nucleoside 5' to the CpG dinucleotide, 3rd nucleoside 5' to the CpG dinucleotide, 4th nucleoside 5' to the CpG dinucleotide, 5th nucleoside 5' to the CpG dinucleotide, 6th nucleoside 5' to the CpG dinucleotide, 2 nucleosides 3' to the CpG dinucleotide, 3rd nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3'
  • the oligonucleotide may be an antisense oligonucleotide.
  • the invention provides CpG-containing oligonucleotides having increased immunostimulatory effects, the oligonucleotide comprising a 2!
  • nucleoside 3' to the CpG dinucleotide 1st nucleoside 5' to the CpG dinucleotide , second nucleoside 5' to the CpG dinucleotide, 3rd nucleoside 5' to the CpG dinucleotide, 4th nucleoside 5' to the CpG dinucleotide, 5th nucleoside 5' to the CpG dinucleotide, 6th nucleoside 5' to the CpG dinucleotide, 2 nucleosides 3' to the CpG dinucleotide, 3rd nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG din
  • the oligonucleotide is not an antisense oligonucleotide.
  • the invention provides a method for inducing an immune response in a mammal, the method comprising administering to the mammal an oligonucleotide comprising a 2!
  • nucleoside 3' to the CpG dinucleotide 1st nucleoside 5' to the CpG dinucleotide , second nucleoside 5' to the CpG dinucleotide, 3rd nucleoside 5' to the CpG dinucleotide, 4th nucleoside 5' to the CpG dinucleotide, 5th nucleoside 5' to the CpG dinucleotide, 6th nucleoside 5' to the CpG dinucleotide, 2 nucleosides 3' to the CpG dinucleotide, 3rd nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG din
  • Figure 1 shows results of a proliferation assay of mouse spleen cells in the presence of no oligonucleotide (C), lipopolysaccharide (LPS), or various oligonucleotides.
  • Figure 2 shows spleen enlargement in mice administered no oligonucleotide or various oligonucleotides.
  • Figure 3 shows preferred embodiments of modified bases.
  • the invention relates to the therapeutic use of oligonucleotides, both in the antisense approach, and as immunostimulatory agents.
  • the patents and publications cited herein reflect the level of knowledge in the field and are hereby incorporated by reference in their entirety. In the event of conflict between any teaching of any reference cited herein and the present specification, the latter shall prevail, for purposes of the invention.
  • the invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides.
  • the methods according to the invention enables both decreasing or increasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.
  • the invention further provides oligonucleotides having optimal levels of immunostimulatory effect for either application and methods for using such oligonucleotides.
  • the present inventor has surprisingly discovered that positional modification of CpG-containing oligonucleotides dramatically affects their immunostimulatory capabilities.
  • 2' substitution including without limitation alkylation or alkoxylation of oligonucleotides at particular positions 5' or 3' to the CpG dinucleotide either enhances or reduces their immunostimulatory effect.
  • the invention provides a method for reducing the immunostimulatory effect of a CpG-containing oligonucleotide.
  • the method according to this aspect of the invention comprises introducing a 2' substituted nucleoside into the oligonucleotide at a position adjacent to, and on the 5' side of the CpG dinucleotide, wherein at least one nucleoside is not a 2'-0-methylribonucleoside and the oligonucleotide is not complementary to the gag or rev gene of human immunodeficiency virus type 1.
  • the method is used to make an oligonucleotide that is complementary to a gene or gene transcript.
  • the oligonucleotide has antisense activity. In some preferred embodiments, only one 2' substituted nucleoside is introduced into the oligonucleotide for each CpG dinucleotide present in the oligonucleotide. In some preferred embodiments, only one 2' substituted nucleoside is introduced into the oligonucleotide. As used for the first three aspects of the invention, the term
  • complementary means having the ability to hybridize to a genomic region, a gene, or an RNA transcript thereof under physiological conditions. Such hybridization is ordinarily the result of base-specific hydrogen bonding between complementary strands, preferably to form Watson-Crick or Hoogsteen base pairs, although other modes of hydrogen bonding, as well as base stacking can also lead to hybridization. As a practical matter, such hybridization can be inferred from the observation of specific gene expression inhibition.
  • antisense activity means that the oligonucleotide, when introduced into a cell or an animal, causes a reduction in the expression of the RNA to which it is complementary.
  • the method according to this aspect of the invention can be conveniently carried out using any of the well-known synthesis techniques by simply using the appropriate 2' substituted monomer synthon in the synthesis process in the cycle immediately following the incorporation of the CpG dinucleotide.
  • Preferred monomers include phosphoramidites, phosphotriesters and H-phosphonates.
  • "introducing a 2! substituted nucleoside into the oligonucleotide at a position adjacent to, and on the 5' side of the CpG dinucleotide” simply means synthesizing an oligonucleotide that has a 2' substituted nucleoside at such a position.
  • the invention provides a CpG-containing oligonucleotide having a reduced immunostimulatory effect, wherein the oligonucleotide comprises a 2' substituted nucleoside at a position adjacent to, and on the 5' side of the CpG dinucleotide, wherein at least one nucleoside is not a 2'-0-methylribonucleoside and the oligonucleotide is not complementary to the gag or rev gene of human immunodeficiency virus type
  • such oligonucleotides will have from about 12 to about 50 nucleotides, most preferably from about 12 to about 35 nucleotides.
  • Preferred oligonucleotides according to this aspect of the invention are complementary to a gene or gene transcript. More preferably, such oligonucleotides have antisense activity.
  • the oligonucleotide has only one 2' substituted nucleoside for each CpG dinucleotide present in the oligonucleotide. In some preferred embodiments, the oligonucleotide has only one 2' substituted nucleoside.
  • the invention provides a method for obtaining an antisense-specific reduction in the expression of a gene in a mammal, the method comprising administering to the mammal a CpG-containing oligonucleotide having a reduced immunostimulatory effect, wherein the oligonucleotide comprises a 2' substituted nucleoside at a position adjacent to, and on the 5' side of the CpG dinucleotide, wherein at least one nucleoside is not a 2'-0-methylribonucleoside and the oligonucleotide is not complementary to the gag or rev gene of human immunodeficiency virus type 1.
  • the oligonucleotide has only one 2' substituted nucleoside for each CpG dinucleotide present in the oligonucleotide. In some preferred embodiments, the oligonucleotide has only one 2' substituted nucleoside.
  • administration of oligonucleotides should be parenteral, oral, sub lingual, transdermal, topical, intranasal, intravaginal, respiratory, intravitreal, or intrarectal.
  • Administration of the therapeutic compositions can be carried out using known procedures at dosages and for periods of time effective to reduce symptoms or surrogate markers of the disease.
  • the therapeutic composition is preferably administered at a sufficient dosage to attain a blood level of oligonucleotide from about 0.01 micromolar to about 10 micromolar.
  • a total dosage of oligonucleotide will range from about 0.01 mg oligonucleotide per patient per day to about
  • oligonucleotide 200 mg oligonucleotide per kg body weight per day.
  • the oligonucleotide may be formulated or naked. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode.
  • one or more measurement is taken of biological effects selected from the group consisting of complement activation, mitogenesis and inhibition of thrombin clot formation.
  • the method according to this aspect of the invention is useful in animal models of disease or gene expression, and is further useful for the therapeutic treatment of human disease.
  • the invention provides a method for increasing the immunostimulatory effect of an immunostimulatory motif (e.g. CpG)- containing oligonucleotide, wherein the oligonucleotide is not an antisense oligonucleotide complementary to Ha-ras or the gag or rev gene of human immunodeficiency virus type 1.
  • an immunostimulatory motif e.g. CpG
  • the method according to this aspect of the invention comprises introducing into the oligonucleotide a 2' substituted nucleoside at a position selected from the group consisting of 1st nucleoside 5' to the CpG dinucleotide , second nucleoside 5' to the CpG dinucleotide, 3rd nucleoside 5' to the CpG dinucleotide, 4th nucleoside 5' to the CpG dinucleotide, 5th nucleoside 5' to the CpG dinucleotide, 6th nucleoside 5' to the CpG dinucleotide, 2 nucleosides 3' to the CpG dinucleotide, 3rd nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3'
  • Preferred monomers include phosphoramidites, phosphotriesters and H-phosphonates.
  • an "antisense oligonucleotide” is an oligonucleotide that is exactly complementary to a gene or gene transcript, and capable of reducing the expression of the gene or gene transcript to which it is exactly complementary.
  • the invention provides immunostimulatory motif (e.g. CpG) containing oligonucleotides having increased immunostimulatory effects, the oligonucleotide comprising a 2! substituted nucleoside at a position selected from the group consisting of 1st nucleoside 5' to the CpG dinucleotide , second nucleoside 5' to the CpG dinucleotide, 3rd nucleoside 5' to the CpG dinucleotide, 4th nucleoside 5' to the CpG dinucleotide, 5th nucleoside 5' to the CpG dinucleotide, 6th nucleoside 5' to the CpG dinucleotide, 2 nucleosides 3' to the CpG dinucleotide, 3rd nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3' to the CpG dinucleotide
  • the oligonucleotide is not an antisense oligonucleotide.
  • Preferred oligonucleotides according to the fourth, fifth and sixth aspects of the invention are from about 6 to about 50 nucleotides in length, and may further comprise modified internucleotide linkages or modified sugars to improve stability.
  • the invention provides a method for inducing an immune response in a mammal, the method comprising administering to the mammal an immunostimulatory motif (e.g. CpG)-containing oligonucleotide comprising a 21 substituted nucleoside at a position selected from the group consisting of 1st nucleoside 5' to the CpG dinucleotide , second nucleoside 5' to the CpG dinucleotide, 3rd nucleoside 5' to the CpG dinucleotide, 4th nucleoside 5' to the CpG dinucleotide, 5th nucleoside 5' to the CpG dinucleotide, 6th nucleoside 5' to the CpG dinucleotide, 2 nucleosides 3' to the CpG dinucleotide, 3rd nucleoside 3' to the CpG dinucleotide, 4th nucleoside 3'
  • administration of oligonucleotides should be parenteral, oral, sub lingual, transdermal, topical, intranasal, intravitreal, or intrarectal.
  • Administration of the therapeutic compositions can be carried out using known procedures at dosages and for periods of time effective to reduce symptoms or surrogate markers of the disease.
  • the therapeutic composition is preferably administered at a sufficient dosage to attain a blood level of oligonucleotide from about 0.01 micromolar to about 10 micromolar. For localized administration, much lower concentrations than this may be effective, and much higher concentrations may be tolerated.
  • a total dosage of oligonucleotide will range from about 0.01 mg oligonucleotide per patient per day to about 200 mg oligonucleotide per kg body weight per day. It may be desirable to administer simultaneously, or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode. In a preferred embodiment, after the composition of matter is administered, one or more measurement is taken of biological effects selected from the group consisting of IL-12 induction, and immune cell mitogenesis.
  • the oligonucleotides may be administered alone, or in combination with specific antigens, which may or may not be physically attached to the oligonucleotide. Such administration may optionally include the use of adjuvants.
  • the method according to this aspect of the invention is useful for model studies of the immune system, and is further useful for the therapeutic treatment of human disease.
  • oligonucleotide includes polymers of two or more deoxyribonucleotide, or any modified nucleoside, including 2'-halo-nucleosides, 2'-0-substitutednucleosides ribonucleosides, deazanucleosides or any combination thereof. Such monomers may be coupled to each other by any of the numerous known internucleoside linkages.
  • these intemucleoside linkages may be nonionic, boronic, phosphodiester, phosphotriester, phosphorothioate, or phosphoramidate linkages, 2'-5' , 3'-5', 3'-3'linkages of any of the forgoing, or combinations thereof.
  • oligonucleotide also encompasses such polymers having chemically modified bases or sugars and/or having additional substituents, including without limitation lipophilic groups, intercalating agents, diamines and adamantane.
  • the term "2'-0-substituted" means substitution of the 2' position of the pentose moiety with a halogen (preferably Cl, Br, or
  • alkyl, aryl or allyl group may be unsubstituted or may be substituted, e.g., with halo, hydroxy, trifluoromethyl, cyano, nitro, acyl, acyloxy, alkoxy, carboxyl, carbalkoxyl, or amino groups; or such 2' substitution may be with a hydroxy group (to produce a ribonucleoside), an amino or a halo group, but not with a 2'-H group.
  • oligonucleotides include oligonucleotides having modified sugars (e.g. arabinose, hexose) and other backbone modifications, e.g., as in peptide nucleic acid and locked nucleic acid. Such oligonucleotides may also have naturally occurring bases or modified heterocyclic rings, including without limitation those shown in Figure 3.
  • modified sugars e.g. arabinose, hexose
  • backbone modifications e.g., as in peptide nucleic acid and locked nucleic acid.
  • Such oligonucleotides may also have naturally occurring bases or modified heterocyclic rings, including without limitation those shown in Figure 3.
  • CpG or "CpG dinucleotide” means the dinucleotide 5'-cytidine-guanidine-3', wherein p is an internucleotide linkage, and wherein the sugar backbone of the dinucleotide deoxyribose, or a modified sugar, or combinations thereof.
  • p is selected from phosphodiester, phosphorothioate, phosphorodithioate, stereospecific (Rp or Sp) phosphorothioate covalent linkages of any of the above.
  • the non- phosphodiester, non-phosphorothioate embodiments will further reduce immunostimulatory effects.
  • p is selected from phosphodiester, phosphorothioate and phosphordithioate.
  • Oligo 1 which contains one CpG motif
  • Oligo 2 which contains two CpG motifs. Both of these oligos have been studied earlier and have shown to be immunostimulatory. To evaluate the immunostimulatory activity of oligonucleotides in the present study, we have used mouse spleen cell proliferation assay.
  • oligos 3, 4 and 5 Two deoxynucleosides were substituted with 2'-OMe leaving one, two and three deoxynucleosides respectively in between site of substitution and CpG motif.
  • the proliferation index of oligo 3, 4, and 5 was 3.42, 8.44, and 10.38 respectively which is an increase of 29, 297 and 400 percent, respectively, compared to oligo 1 (Fig.l). Substitution of remaining deoxynucleosides further towards 5'-end than in oligo 5 showed no further increase in proliferation index (data not shown).
  • oligo 7, 8, 9, 10 and 11 Similar substitutions were made in oligo 1 in the 3'- flanking region to CpG motif. Oligo 7, 8, 9, 10 and 11 were synthesized in which two deoxynucleosides were substituted with 2'-OMe leaving one, two, three, four and five deoxynucleosides respectively in between CpG motif and 2'-OMe substitution.
  • the proliferation index of oligo 7, 8, 9, 10 and 11 were 3.63, 7.22, 7.01, 8.85, and 9.24 respectively. Compared to oligo 1, the increase in proliferation index for oligo 7, 8, 9, 10 and 11 was 39, 231, 221, 317 and 338 percent respectively.
  • Oligo 15 contains two CpG motifs. Oligo 15 had a proliferation index of 5.83 at a concentration of 0.1 ⁇ mL. Substitution of two deoxynucleosides at 5'- ends of individual CpG motifs leaving two deoxynucleosides in between CpG motif and substitution with 2'-OMe, oligo
  • Example 2 Effect of nuclease stability on immunostimulatory activity
  • Oligo 13 was synthesized in which four continuous deoxynucleosides at the 3'- end of oligo 1 were substituted with 2'- OMe, which results in a significant increase in stability towards nucleases.
  • Oligo 13 had a proliferation index of 11.92, which is an increase of about 480% compared to oligo 1 (Fig. 1). Further modification of oligo 13 by substitution of two deoxynucleosides at 5'-end (oligo 14) did not result in further increase in proliferation index.
  • Oligo 15 caused 175 percent increase of spleen weight compared to untreated mice.
  • Oligo 16 in which two of the 5'-end CpG motifs were substituted with 2'-OMe, caused a 93 percent increase in spleen weight compared to oligo 15 (Fig. 2).
  • Oligo 13 which is metabolically stable compared to oligo 1, showed 114 percent increase in spleen weight compared to Oligo 1, and was in agreement with cell proliferation data. Similar results were observed with Oligo 14, which has increased metabolic stability and substituted at the 5'-end of CpG motif (Fig. 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PCT/US2000/022284 1999-08-13 2000-08-14 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES Ceased WO2001012804A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002381993A CA2381993A1 (en) 1999-08-13 2000-08-14 Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
DK00955527T DK1200580T3 (da) 1999-08-13 2000-08-14 Modulering af oligonukleotid-CpG-medieret immunstimulering ved positionel modifikation
MXPA02001610A MXPA02001610A (es) 1999-08-13 2000-08-14 Modulacion de estimulacion inmune mediada por oligonucleotido cpg mediante la modificacion posicional de nucleosidos.
DE60017259T DE60017259T2 (de) 1999-08-13 2000-08-14 Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden
JP2001517689A JP5268214B2 (ja) 1999-08-13 2000-08-14 ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ−媒体免疫刺激の変調
AT00955527T ATE286534T1 (de) 1999-08-13 2000-08-14 Modulierung der durch cpg-oligonukleotide verursachten immunstimulierung durch positionsbedingte veränderung von nukleosiden
AU67720/00A AU783745B2 (en) 1999-08-13 2000-08-14 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP00955527A EP1200580B1 (en) 1999-08-13 2000-08-14 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14879899P 1999-08-13 1999-08-13
US60/148,798 1999-08-13

Publications (2)

Publication Number Publication Date
WO2001012804A2 true WO2001012804A2 (en) 2001-02-22
WO2001012804A3 WO2001012804A3 (en) 2001-09-07

Family

ID=22527436

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022284 Ceased WO2001012804A2 (en) 1999-08-13 2000-08-14 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES

Country Status (13)

Country Link
US (1) US6476000B1 (https=)
EP (2) EP2314693A3 (https=)
JP (2) JP5268214B2 (https=)
KR (1) KR100651294B1 (https=)
AT (1) ATE286534T1 (https=)
AU (2) AU783745B2 (https=)
CA (2) CA2381993A1 (https=)
DE (1) DE60017259T2 (https=)
DK (1) DK1200580T3 (https=)
ES (1) ES2233426T3 (https=)
MX (1) MXPA02001610A (https=)
PT (1) PT1200580E (https=)
WO (1) WO2001012804A2 (https=)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083503A3 (en) * 2000-05-01 2002-07-18 Hybridon Inc MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
WO2003000922A2 (en) 2001-06-21 2003-01-03 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
WO2004074454A2 (en) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
US7038029B2 (en) 2002-05-30 2006-05-02 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7176296B2 (en) 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
WO2007055704A2 (en) 2005-11-07 2007-05-18 Idera Pharmaceuticals Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
EP1992635A1 (en) 2002-12-23 2008-11-19 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2060269A2 (en) 2003-12-08 2009-05-20 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
US7569554B2 (en) 2003-05-16 2009-08-04 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
US7595305B2 (en) 2003-01-16 2009-09-29 Idera Pharmaceuticals Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7615539B2 (en) 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US7709617B2 (en) 2003-07-15 2010-05-04 Idera Pharmaceuticals, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
US7713529B2 (en) 1994-07-15 2010-05-11 University Of Iowa Research Foundation Methods for treating and preventing infectious disease
US7723500B2 (en) 1994-07-15 2010-05-25 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7741297B2 (en) 2002-02-04 2010-06-22 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
EP2179061A4 (en) * 2007-08-15 2010-09-08 Idera Pharmaceuticals Inc GREAT LIKE RECEPTOR MODULATORS
WO2011005942A3 (en) * 2009-07-08 2011-04-28 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
US8188254B2 (en) 2003-10-30 2012-05-29 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US8309527B2 (en) 1994-07-15 2012-11-13 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US8586555B2 (en) 2001-08-07 2013-11-19 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
US8871732B2 (en) 2002-12-23 2014-10-28 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
EP2982679A1 (en) * 2005-10-12 2016-02-10 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
WO2017057540A1 (ja) * 2015-09-30 2017-04-06 塩野義製薬株式会社 免疫賦活活性を有する核酸誘導体
JPWO2018179172A1 (ja) * 2017-03-29 2020-02-06 塩野義製薬株式会社 免疫賦活活性を有する核酸誘導体
US10940201B2 (en) 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1322655B1 (en) 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US20060142202A1 (en) * 2000-12-08 2006-06-29 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
WO2003020884A2 (en) 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
AU2002343728A1 (en) * 2001-11-16 2003-06-10 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
NZ534566A (en) * 2002-02-22 2007-02-23 3M Innovative Properties Co Method of reducing and treating UVB-induced immunosuppression
NZ538812A (en) 2002-08-15 2009-02-28 3M Innovative Properties Co Immunostimulatory compositions and methods of stimulating an immune response
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
KR100681470B1 (ko) * 2003-03-03 2007-02-12 연세대학교 산학협력단 면역반응 증진용 올리고뉴크레오타이드
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
MXPA05009694A (es) * 2003-03-13 2005-10-20 3M Innovative Properties Co Metodos para mejorar la calidad de la piel.
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
AU2004244962A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
RU2006102188A (ru) * 2003-07-31 2006-07-10 ЗМ Инновейтив Пропертиз Компани (US) Биоактивные композиции, включающие триазины
CA2534625A1 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
BRPI0413558A (pt) 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
AU2004266162A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
WO2005020912A2 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
MXPA06002199A (es) 2003-08-27 2006-05-22 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi.
JP2007504172A (ja) * 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 粘膜に関連した症状の処置に関する方法
CA2537763A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
EP1680080A4 (en) * 2003-10-31 2007-10-31 3M Innovative Properties Co NEUTROPHILIC ACTIVATION THROUGH COMPOUNDS TO MODIFY THE IMMUNE RESPONSE
WO2005048945A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
US7897767B2 (en) 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
WO2005051317A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
JP2007517055A (ja) * 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答の増強
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
CA2564855A1 (en) * 2004-04-28 2005-10-28 3M Innovative Properties Company Compositions and methods for mucosal vaccination
AU2005294805B2 (en) 2004-05-28 2012-02-16 Oryxe A mixture for transdermal delivery of low and high molecular weight compounds
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
AU2005326144A1 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006026470A2 (en) * 2004-08-27 2006-03-09 3M Innovative Properties Company Hiv immunostimulatory compositions
EP1804583A4 (en) * 2004-10-08 2009-05-20 3M Innovative Properties Co ADJUVANT FOR DNA VACCINE
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2594253C (en) 2004-12-30 2015-08-11 3M Innovative Properties Company Treatment for cutaneous metastases
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
JP2008538550A (ja) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ，インコーポレイテッド ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物
JP2008535832A (ja) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ピラゾロピリジン−１，４−ジアミン、およびそのアナログ
US7776834B2 (en) * 2005-11-07 2010-08-17 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
AU2009302468A1 (en) * 2008-10-06 2010-04-15 Idera Pharmaceuticals, Inc. Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
KR101985382B1 (ko) 2010-11-19 2019-06-03 이데라 파마슈티칼즈, 인코포레이티드 톨-유사 수용체 기반 면역 반응을 조절하기 위한 면역 조절 올리고뉴클레오타이드(ｉｒｏ) 화합물
WO2012167088A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
EP3024476A1 (en) 2013-07-26 2016-06-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
KR20180053318A (ko) 2015-09-17 2018-05-21 제이알엑스 바이오테크놀로지, 인코포레이티드 피부 수화 또는 보습을 향상시키기 위한 접근법
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
JP2021516045A (ja) 2018-02-28 2021-07-01 ファイザー・インク Ｉｌ−１５バリアントおよびその使用
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
SI3797121T1 (sl) 2018-05-23 2024-09-30 Pfizer Inc. Protitelesa, specifična za CD3, in njihova uporaba
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
JP7369297B2 (ja) 2019-12-17 2023-10-25 ファイザー・インク Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
TW202216779A (zh) 2020-07-17 2022-05-01 美商輝瑞股份有限公司 治療性抗體類和彼等之用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149798A (en) 1989-04-06 1992-09-22 Worcester Foundation For Experimental Biology Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses
US6153595A (en) * 1990-08-16 2000-11-28 Isis Pharmaceuticals Inc. Composition and method for treatment of CMV infections
CA2126451A1 (en) * 1991-12-24 1993-07-08 Brett P. Monia Compositions and methods for modulating .beta.-amyloid
US6235723B1 (en) * 1992-03-16 2001-05-22 Isis Pharmaceuticals , Inc. Antisense oligonucleotide modulation of human protein kinase C-δ expression
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5591721A (en) * 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5968909A (en) 1995-08-04 1999-10-19 Hybridon, Inc. Method of modulating gene expression with reduced immunostimulatory response
US5652356A (en) * 1995-08-17 1997-07-29 Hybridon, Inc. Inverted chimeric and hybrid oligonucleotides
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
WO1999009154A2 (en) * 1997-08-19 1999-02-25 Hybridon, Inc. Novel hiv-specific synthetic oligonucleotides and methods of their use
US6228642B1 (en) * 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8309527B2 (en) 1994-07-15 2012-11-13 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US7713529B2 (en) 1994-07-15 2010-05-11 University Of Iowa Research Foundation Methods for treating and preventing infectious disease
US7723500B2 (en) 1994-07-15 2010-05-25 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8008266B2 (en) 1994-07-15 2011-08-30 University Of Iowa Foundation Methods of treating cancer using immunostimulatory oligonucleotides
WO2001083503A3 (en) * 2000-05-01 2002-07-18 Hybridon Inc MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
US7115579B2 (en) 2000-05-01 2006-10-03 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7176296B2 (en) 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP1404873A4 (en) * 2001-06-21 2009-03-25 Dynavax Tech Corp CHIMERIC IMMUNOMODULAR COMPOUNDS AND METHOD FOR THEIR USE
EP2423335A3 (en) * 2001-06-21 2012-08-08 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US9028845B2 (en) 2001-06-21 2015-05-12 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same-IV
WO2003000922A2 (en) 2001-06-21 2003-01-03 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US8586555B2 (en) 2001-08-07 2013-11-19 Dynavax Technologies Corporation Immunomodulatory compositions, formulations, and methods for use thereof
US7812000B2 (en) 2001-10-24 2010-10-12 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7407944B2 (en) 2001-10-24 2008-08-05 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7517862B2 (en) 2001-10-24 2009-04-14 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7749975B2 (en) 2001-10-24 2010-07-06 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7741297B2 (en) 2002-02-04 2010-06-22 Oncothyreon Inc. Immunostimulatory, covalently lipidated oligonucleotides
US7381807B2 (en) 2002-05-30 2008-06-03 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7943316B2 (en) 2002-05-30 2011-05-17 David Horn, Llc Immunostimulatory oligonucleotides and uses thereof
US7038029B2 (en) 2002-05-30 2006-05-02 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
EP1992635A1 (en) 2002-12-23 2008-11-19 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7745606B2 (en) 2002-12-23 2010-06-29 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US9422564B2 (en) 2002-12-23 2016-08-23 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US11312965B2 (en) 2002-12-23 2022-04-26 Trisalus Life Sciences, Inc. Immunostimulatory sequence oligonucleotides and methods of using the same
US10196643B2 (en) 2002-12-23 2019-02-05 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US8871732B2 (en) 2002-12-23 2014-10-28 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7595305B2 (en) 2003-01-16 2009-09-29 Idera Pharmaceuticals Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US8153608B2 (en) 2003-01-16 2012-04-10 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7851453B2 (en) 2003-01-16 2010-12-14 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7863250B2 (en) 2003-01-16 2011-01-04 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7632822B2 (en) 2003-01-16 2009-12-15 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
US7851454B2 (en) 2003-02-07 2010-12-14 Idera Pharmaceutials, Inc. Short immunomodulatory oligonucleotides
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
WO2004074454A2 (en) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
US7875594B2 (en) 2003-05-16 2011-01-25 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
US7569554B2 (en) 2003-05-16 2009-08-04 Idera Pharmaceuticals, Inc. Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents
EP2363141A1 (en) 2003-07-15 2011-09-07 Idera Pharmaceuticals, Inc. Compsition comprising two oligonucleotides linked directly at their 3'ends wherein at leat one oligonucleotide has an accessible 5'end and the compound further comprising IL-2 used for synergistically stimulating an immune response in a patient.
US7709617B2 (en) 2003-07-15 2010-05-04 Idera Pharmaceuticals, Inc. Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
US7615539B2 (en) 2003-09-25 2009-11-10 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
US8188254B2 (en) 2003-10-30 2012-05-29 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
US7713535B2 (en) 2003-12-08 2010-05-11 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
EP2060269A2 (en) 2003-12-08 2009-05-20 Hybridon, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
EP2982679A1 (en) * 2005-10-12 2016-02-10 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
WO2007055704A2 (en) 2005-11-07 2007-05-18 Idera Pharmaceuticals Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
US7470674B2 (en) 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2402442A2 (en) 2005-11-07 2012-01-04 Idera Pharmaceuticals Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2371956A2 (en) 2005-11-07 2011-10-05 Idera Pharmaceuticals Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP2179061A4 (en) * 2007-08-15 2010-09-08 Idera Pharmaceuticals Inc GREAT LIKE RECEPTOR MODULATORS
WO2011005942A3 (en) * 2009-07-08 2011-04-28 Idera Pharmaceuticals, Inc. Oligonucleotide-based compounds as inhibitors of toll-like receptors
WO2017057540A1 (ja) * 2015-09-30 2017-04-06 塩野義製薬株式会社 免疫賦活活性を有する核酸誘導体
JPWO2017057540A1 (ja) * 2015-09-30 2018-06-21 塩野義製薬株式会社 免疫賦活活性を有する核酸誘導体
US10940201B2 (en) 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
JPWO2018179172A1 (ja) * 2017-03-29 2020-02-06 塩野義製薬株式会社 免疫賦活活性を有する核酸誘導体

Also Published As

Publication number Publication date
DE60017259T2 (de) 2005-12-08
AU6772000A (en) 2001-03-13
JP5268214B2 (ja) 2013-08-21
US6476000B1 (en) 2002-11-05
AU2005242217A1 (en) 2006-01-12
JP2011019527A (ja) 2011-02-03
KR20020059586A (ko) 2002-07-13
AU783745B2 (en) 2005-12-01
DK1200580T3 (da) 2005-04-11
KR100651294B1 (ko) 2006-11-28
EP1200580B1 (en) 2005-01-05
CA2381993A1 (en) 2001-02-22
DE60017259D1 (de) 2005-02-10
MXPA02001610A (es) 2003-07-21
EP2314693A3 (en) 2012-11-28
EP1200580A2 (en) 2002-05-02
ES2233426T3 (es) 2005-06-16
ATE286534T1 (de) 2005-01-15
EP2314693A2 (en) 2011-04-27
CA2784789A1 (en) 2001-02-22
PT1200580E (pt) 2005-03-31
JP2003526628A (ja) 2003-09-09
WO2001012804A3 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
AU783745B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP1278761B1 (en) MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
CA2398432C (en) Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
US7176296B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
AU2001257366A1 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7105495B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP1496121A2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
AU2005218065B2 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
AU2006200811A1 (en) Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 67720/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000955527

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020027001695

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2381993

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001610

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2000955527

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027001695

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000955527

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 67720/00

Country of ref document: AU